Publikationen 2003 - 2004

  1. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D, Sykora KW, Niemeyer C, Reinhardt D, Vormoor J, Gruhn B, Lang P, Greil J, Handgretinger R, Niethammer D, Klingebiel T, Beck JF: Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004;33:815-821. www.ncbi.nlm.nih.gov/pubmed/14990984
  2. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T: Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004;22:4384-4393. www.ncbi.nlm.nih.gov/pubmed/15514380
  3. Creutzig U, Kaspers GJ: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2004;22:3432-3433. www.ncbi.nlm.nih.gov/pubmed/15310791
  4. Creutzig U, Reinhardt D, Zimmermann M: Prognostic relevance of risk groups in the pediatric AML-BFM trials 93 and 98. Ann Hematol 2004;83 Suppl 1:S112-S116. www.ncbi.nlm.nih.gov/pubmed/15124699
  5. Hubeek I, Peters GJ, Broekhuizen AJ, Talianidis I, Schouten van Meeteren AY, van Wering ER, Gibson B, Creutzig U, Kaspers GJ: Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity. Nucleosides Nucleotides Nucleic Acids 2004;23:1351-1356. www.ncbi.nlm.nih.gov/pubmed/15571257
  6. Hubeek I, Litvinova E, Peters GJ, Broekhuizen R, Haarman EG, Huismans DR, Cloos J, Zwaan CM, Fleischhack G, Creutzig U, Kaspers GJ: The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. Int J Oncol 2004;25:1823-1829. www.ncbi.nlm.nih.gov/pubmed/15547723
  7. Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U: Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004;18:72-77. www.ncbi.nlm.nih.gov/pubmed/14586478
  8. Metzler M, Strissel PL, Strick R, Niemeyer C, Roettgers S, Borkhardt A, Harbott J, Ludwig WD, Stanulla M, Schrappe M, Reinhardt D, Creutzig U, Beck JD, Rascher W, Repp R, Langer T: Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2004;41:291-296. www.ncbi.nlm.nih.gov/pubmed/15334554
  9. Reinhardt D, Diekamp S, Fleischhack G, Corbacioglu C, Jürgens H, Dworzak M, Kaspers G, Creutzig U, Zwaan CM: Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie 2004;27:269-272. www.ncbi.nlm.nih.gov/pubmed/15249716
  10. Reinhardt D, Creutzig U: Akute myeloische Leukämien im Kindesalter. Journal Onkologie 2004;8:30-34.
  11. Reinhardt D, Kurzknabe E, Löffler H, Creutzig U: Akute Leukämien im Kindesalter mit besonderer Berücksichtigung der morphologischen Diagnostik. pädiatrische praxis 2004;64:395-418.
  12. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, Ludwig WD, Wuchter C: High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004;10:3737-3744. www.ncbi.nlm.nih.gov/pubmed/15173080
  13. Wulf GG, Modlich S, Inagaki N, Reinhardt D, Schroers R, Griesinger F, Trumper L: ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 2004;89:1395-1397. www.ncbi.nlm.nih.gov/pubmed/15531465
  14. Creutzig U, Henze G, Bielack S, Herold R, Kaatsch P, Klusmann J-H, Graf N, Reinhardt D, Schrappe M, Zimmermann M, Jürgens H: Krebserkrankungen bei Kindern: Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Arztebl 2003;100:A842-A852.
  15. Creutzig U: Treatment of acute myeloid leukemia in children; in Pui CH, (ed): Treatment of Acute Leukemias, New Directions for Clinical Research (St. Jude Children's Research Hospital, Memphis,TN). Totowa,NJ, Human Press Inc, 2003, pp 237-254.
  16. Creutzig U, Zimmermann M, Reinhardt D, Lehrnbecher T: [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93]. Klin Padiatr 2003;215:151-158. www.ncbi.nlm.nih.gov/pubmed/12778355
  17. Creutzig U, Zimmermann M, Hannemann J, Kramer I, Herold R, Henze G: [Quality management within the competence network of paediatric oncology and haematology]. Klin Padiatr 2003;215:338-340. www.ncbi.nlm.nih.gov/pubmed/14677099
  18. Creutzig U, Zimmermann M, Hannemann J, Krämer I, Herold R, Henze G: Qualitätssicherung im Kompetenznetz Pädiatrische Onkologie und Hämatologie. Klin Pädiatr 2003;6:338-340.
  19. Hempel G, Reinhardt D, Creutzig U, Boos J: Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol 2003;56:370-377. www.ncbi.nlm.nih.gov/pubmed/12968981
  20. Kaaijk P, Kaspers GJ, van Wering ER, Broekema GJ, Loonen AH, Hahlen K, Schmiegelow K, Janka-Schaub GE, Henze G, Creutzig U, Veerman AJ: Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer 2003;88:775-781. www.ncbi.nlm.nih.gov/pubmed/12618889
  21. Langer T, Metzler M, Reinhardt D, Viehmann S, Borkhardt A, Reichel M, Stanulla M, Schrappe M, Creutzig U, Ritter J, Leis T, Jacobs U, Harbott J, Beck JD, Rascher W, Repp R: Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer 2003;36:393-401. www.ncbi.nlm.nih.gov/pubmed/12619163
  22. Lanvers C, Reinhardt D, Dubbers A, Wagner-Bohn A, Creutzig U, Ritter J, Boos J: Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Med Pediatr Oncol 2003;40:293-301. www.ncbi.nlm.nih.gov/pubmed/12652617
  23. Reinhardt D, Houliara K, Pekrun A, Lakomek M, Krone B: Impact of Conventional Chemotherpy on Levels of Antibodies Against Vaccine-Preventable Diseases in Children Treated for Cancer. Scand J Infect Dis 2003;35:851-857.
  24. Viehmann S, Teigler-Schlegel A, Bruch J, Langebrake C, Reinhardt D, Harbott J: Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003;17:1130-1136.
  25. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003;102:2387-2394. www.ncbi.nlm.nih.gov/pubmed/12816873
  26. Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bokkerink JP, Tissing WJ, Samuelsson U, Feingold J, Creutzig U, Kaspers GJ: Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003;101:3868-3871. www.ncbi.nlm.nih.gov/pubmed/12543868
  27. Zwaan ChM, Reinhardt D, Jürgens H, Huismans DR, Hahlen K, Smith OP, Biondi A, van Wering ER, Feingold J, Kaspers GJ: Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003;17:468-470. www.ncbi.nlm.nih.gov/pubmed/12592351
  28. Zwaan ChM, Kaspers GJL, Pieters R, Huismans DR, Creutzig U, Hählen K, van Wering ER, Veerman AJP: Age-Related Differences in Cellular Drug Resistance in Children with Acute Myeloid Leukemia (AML). Haematol Blood Transf 2003;41:291-298.
Suchen
Benutzeranmeldung